Durvalumab: A Review in Extensive-Stage SCLC.

ABSTRACT: Durvalumab (IMFINZI^®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivotal phase III CASPIAN trial in previously untreated adults with ES-SCLC, the addition of durvalumab to chemotherapy for up to 4 cycles followed by maintenance durvalumab was associated with a significantly longer overall survival and a favourable hazard ratio for progression-free survival compared with chemotherapy alone for up to 6 cycles. A higher proportion of patients in the durvalumab plus chemotherapy group had an objective response compared with the chemotherapy alone group. The

SUBMITTER: Al-Salama ZT 

PROVIDER: S-EPMC8648650 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature